We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells.
- Authors
Mao, Yuan; Fan, Weifei; Hu, Hao; Zhang, Louqian; Michel, Jerod; Wu, Yaqin; Wang, Jun; Jia, Lizhou; Tang, Xiaojun; Xu, Li; Chen, Yan; Zhu, Jin; Feng, Zhenqing; Xu, Lin; Yin, Rong; Tang, Qi
- Abstract
Background: Cancer/testis antigens (CTAs) are a special type of tumor antigen and are believed to act as potential targets for cancer immunotherapy. Methods: In this study, we first screened a rational CTA MAGE-A1 for lung adenocarcinoma (LUAD) and explored the detailed characteristics of MAGE-A1 in LUAD development through a series of phenotypic experiments. Then, we developed a novel MAGE-A1-CAR-T cell (mCART) using lentiviral vector based on our previous MAGE-A1-scFv. The anti-tumor effects of this mCART were finally investigated in vitro and in vivo. Results: The results showed striking malignant behaviors of MAGE-A1 in LUAD development, which further validated the rationality of MAGE-A1 as an appropriate target for LUAD treatment. Then, the innovative mCART was successfully constructed, and mCART displayed encouraging tumor-inhibitory efficacy in LUAD cells and xenografts. Conclusions: Taken together, our data suggest that MAGE-A1 is a promising candidate marker for LUAD therapy and the MAGE-A1-specific CAR-T cell immunotherapy may be an effective strategy for the treatment of MAGE-A1-positive LUAD.
- Subjects
CHIMERIC antigen receptors; TUMOR antigens; LUNGS
- Publication
Journal of Hematology & Oncology, 2019, Vol 12, Issue 1, pN.PAG
- ISSN
1756-8722
- Publication type
Article
- DOI
10.1186/s13045-019-0793-7